Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

China’s NMPA grants conditional approval for Apollomics’ NSCLC drug

Apollomics’ Chinese partner, Avistone Biotechnology, received a conditional approval for Velbretinib from China's NMPA.

Akosua Mireku November 17 2023

The National Medical Products Administration (NMPA) of China granted conditional approval to biotech Apollomics for the commercialisation of its non-small cell lung cancer (NSCLC) treatment.

Velbretinib (APL-101) is an orally bioavailable small molecule that treats NSCLC patients with MET exon 14 skipping alterations by inhibiting c-Met. This is a protein that is key in the tumour growth pathway. MET exon 14 skipping mutations occur in approximately 3% of cases of NSCLC. This condition is most diagnosed in adults aged over 70 with a smoking history.

China’s NMPA grants conditional approvals to treatments for diseases that are severely life-threatening and there is no effective treatment method. Under the terms of an agreement, the company’s Chinese partner, Avistone, holds the drug’s exclusive rights in China, Hong Kong and Macau. Apollomics holds the rights for the US and all other countries.

California-headquartered Apollomics is also in active discussions with the US Food and Drug Administration (FDA) pursuing a US approval, as per a 16 November press release. This will be based on clinical data from the Phase II multi-cohort SPARTA trial (NCT03175224) and Avistone Biotechnology’s Phase II KUNPENG trial (NCT04258033) in China.

Apollomics recently announced the expansion of the SPARTA Phase II study to include patients with EGFR-mutated NSCLC and the addition of an extra cohort to study the velbretinib monotherapy in histology-agnostic solid tumours with wild-type MET gene that have high expression of c-MET and hepatocyte growth factor. The Washington University School of Medicine is also evaluating the safety and efficacy of combining velbretinib with AstraZeneca’s Tagrisso (osimertinib) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC in a separate Phase I/II study.

In an October 31 press release, Apollomics’s CEO Dr Guo-Liang Yu said: “The NMPA approval of velbretinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. Apollomics extends its full support and congratulations to Avistone on this significant achievement.”

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.